84 related articles for article (PubMed ID: 10073506)
1. Genetic control of anticoagulation.
Mannucci PM
Lancet; 1999 Feb; 353(9154):688-9. PubMed ID: 10073506
[No Abstract] [Full Text] [Related]
2. Genetic susceptibility to hemorrhagic complications during warfarin therapy.
Tabrizi AR; Freeman BD; Buchman TG; Zehnbauer BA
Surgery; 2001 May; 129(5):645-6. PubMed ID: 11331459
[No Abstract] [Full Text] [Related]
3. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
Margaglione M; Brancaccio V; Ciampa A; Di Minno G
Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
[No Abstract] [Full Text] [Related]
4. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9*3 allelic variant and bleeding complications.
Ogg MS; Brennan P; Meade T; Humphries SE
Lancet; 1999 Sep; 354(9184):1124. PubMed ID: 10509530
[No Abstract] [Full Text] [Related]
6. Avoiding overanticoagulation: pharmacogenomics or pragmatism?
Baglin T
Thromb Haemost; 2001 May; 85(5):945-6. PubMed ID: 11372698
[No Abstract] [Full Text] [Related]
7. Major bleeding caused by warfarin in a genetically susceptible patient.
Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y
Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436
[TBL] [Abstract][Full Text] [Related]
8. Warfarin dose requirement and CYP2C9 polymorphisms.
Halkin H; Lubetsky A
Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
[No Abstract] [Full Text] [Related]
9. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
Taube J; Halsall D; Baglin T
Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881
[TBL] [Abstract][Full Text] [Related]
10. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
Ablin J; Cabili S; Lagziel A; Peretz H
Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
[No Abstract] [Full Text] [Related]
11. CYP2C9 polymorphism and warfarin dose requirements.
Daly AK; Day CP; Aithal GP
Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
[No Abstract] [Full Text] [Related]
12. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
[No Abstract] [Full Text] [Related]
13. Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population.
Zarza J; Hermida J; Montes R; Alberca I; López ML; Rocha E
Blood; 2002 Jul; 100(2):734. PubMed ID: 12123234
[No Abstract] [Full Text] [Related]
14. Mutations of the CYP2C9 gene and the response to warfarin.
Yasar U; Oscarson M; Eliasson E; Sjöqvist F
Surgery; 2001 Mar; 129(3):384. PubMed ID: 11231472
[No Abstract] [Full Text] [Related]
15. Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms.
Tabrizi AR; McGrath SD; Blinder MA; Buchman TG; Zehnbauer BA; Freeman BD
Am J Hematol; 2001 Jun; 67(2):144-6. PubMed ID: 11343389
[TBL] [Abstract][Full Text] [Related]
16. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
[TBL] [Abstract][Full Text] [Related]
17. Genetic modulation of oral anticoagulation with warfarin.
Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for anticoagulation-related bleeding complications.
Jolobe O
QJM; 2008 May; 101(5):419. PubMed ID: 18344249
[No Abstract] [Full Text] [Related]
19. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
20. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
